Utilizing the SKG mouse model—characterized by peripheral arthritis, enthesitis, and spondylitis resembling human SpA [30]—we have demonstrated that anti-VEGF-A therapy targets core pathological features of the disease. The gene discussed is VEGFA; the disease is spondylitis.